Innate Pharma S.A.
Ticker
IPHA
ISIN
-
Price
USD 2.94
Change Today
+0.04 / 1.397 %
Price 1 year ago
2.88 / 1.924 %
Market Capitalization
229,489,616.00
52 Week Low
2.17
52 Week High
3.50
200 Day Moving Average
2.61
50-day Moving Average
2.53
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Sector
Healthcare
Industry
Biotechnology
Country
France
Exchange
NMS
Earnings Per Share
-0.8
P/E Ratio
-
Debt/Equity Ratio
78.024
Beta
0.322137
Ebitda
-12,020,000.00
Ebitda Margins
-0.21
Enterprise to Ebitda
-14.15
Enterprise Value
170,119,392.00
Target Price
8.32
Estimated Price
-
Book Value
0.68
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
Company | Name | Correlation |
---|---|---|
300181.SZ | ZHEJIANG JOLLY PHA | -0.36 |
600866.SS | STAR LAKE BIOSCIENCE CO INC Z | -0.24 |
600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | -0.14 |
2370.T | MEDINET CO LTD | -0.14 |
IMU.AX | IMUGENE FPO | -0.05 |
300204.SZ | STAIDSON (BEIJING) | -0.03 |
ALPHA.PA | PHARNEXT | 0.08 |
300009.SZ | ANHUI ANKE BIOTECH | 0.09 |
0775.HK | CKLIFE SCIENCES | 0.10 |
2137.HK | BRII-B | 0.12 |
1530.HK | 3SBIO | 0.17 |
1873.HK | VIVA BIOTECH | 0.20 |
300363.SZ | PORTON PHARMA SOLU | 0.22 |
300147.SZ | XIANGXUE PHARMACEU | 0.24 |
300122.SZ | CHONGQING ZHIFEI B | 0.25 |
ATHX | Athersys, Inc. | 0.29 |
002007.SZ | HUALAN BIOLOGICAL | 0.30 |
2269.HK | WUXI BIO | 0.31 |
1801.HK | INNOVENT BIO | 0.32 |
TRX.L | TISSUE REGENIX GROUP PLC | 0.32 |
TMBR | Timber Pharmaceuticals, Inc. | 0.35 |
600201.SS | JINYU BIO-TECHNOLOGY CO LTD | 0.40 |
BLUE | bluebird bio, Inc. | 0.40 |
002252.SZ | S/H RAAS BLOOD PRO | 0.42 |
1177.HK | SINO BIOPHARM | 0.43 |
AKBA | Akebia Therapeutics, Inc. | 0.46 |
DNA | Ginkgo Bioworks Holdings, Inc. | 0.47 |
300497.SZ | JIANGXI FUSHINE PH | 0.62 |
Similar companies
Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
---|---|---|---|---|---|---|---|---|---|
ALPHA.PA | PHARNEXT | Issy-les-Moulineaux | France | EUR | PAR | 2.86 | -0.65 | 40 | https://www.pharnext.com |
1177.HK | SINO BIOPHARM | Wan Chai | Hong Kong | HKD | HKG | 0.48 | 17.58 | 25579 | https://www.sinobiopharm.com |
0775.HK | CKLIFE SCIENCES | Tai Po | Hong Kong | HKD | HKG | 0.40 | 32.46 | 1855 | https://www.ck-lifesciences.com |
DNA | Ginkgo Bioworks Holdings, Inc. | Boston | United States | USD | NYQ | -1.24 | 641 | https://www.ginkgobioworks.com | |
002252.SZ | S/H RAAS BLOOD PRO | Shanghai | China | CNY | SHZ | 0.21 | 19.62 | 2966 | https://www.raas-corp.com |
002007.SZ | HUALAN BIOLOGICAL | Xinxiang | China | CNY | SHZ | 0.03 | 19.25 | 2927 | https://www.hualanbio.com |
600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | Suzhou | China | CNY | SHH | 0.56 | -710.43 | https://www.600200.com | |
600866.SS | STAR LAKE BIOSCIENCE CO INC Z | Zhaoqing | China | CNY | SHH | 0.35 | 21.35 | 2608 | https://www.starlake.com.cn |
TRX.L | TISSUE REGENIX GROUP PLC | Garforth | United Kingdom | GBp | LSE | 1.40 | -10.94 | 79 | https://www.tissueregenix.com |
2269.HK | WUXI BIO | Wuxi | China | HKD | HKG | 0.91 | 85.17 | 9864 | https://www.wuxibiologics.com |
IMU.AX | IMUGENE FPO | Sydney | Australia | AUD | ASX | 2.28 | -30.30 | https://www.imugene.com | |
600201.SS | JINYU BIO-TECHNOLOGY CO LTD | Hohhot | China | CNY | SHH | 0.31 | 18.76 | 1580 | https://www.jinyu.com.cn |
TMBR | Timber Pharmaceuticals, Inc. | Basking Ridge | United States | USD | ASE | 0.19 | 5 | https://www.timberpharma.com | |
300181.SZ | ZHEJIANG JOLLY PHA | Huzhou | China | CNY | SHZ | 0.10 | 18.50 | 2132 | https://www.zuoli.com |
CLVS | Clovis Oncology, Inc. | Boulder | United States | USD | NMS | 0.49 | -3.78 | 413 | https://www.clovisoncology.com |
ATHX | Athersys, Inc. | Cleveland | United States | USD | NCM | -1.30 | -0.60 | 104 | https://www.athersys.com |
VTGN | VistaGen Therapeutics, Inc. | South San Francisco | United States | USD | NCM | 1.06 | 0.75 | 36 | https://www.vistagen.com |
300009.SZ | ANHUI ANKE BIOTECH | Hefei | China | CNY | SHZ | 0.38 | 19.32 | https://www.ankebio.com | |
300122.SZ | CHONGQING ZHIFEI B | Chongqing | China | CNY | SHZ | 0.77 | 11.89 | 4800 | https://www.zhifeishengwu.com |
2370.T | MEDINET CO LTD | Tokyo | Japan | JPY | JPX | 1.34 | -2.69 | 92 | https://www.medinet-inc.co.jp |
2137.HK | BRII-B | Beijing | China | HKD | HKG | -5.41 | 113 | https://www.briibio.com | |
1530.HK | 3SBIO | Shenyang | China | HKD | HKG | 0.84 | 6.75 | 5292 | https://www.3sbio.com |
1801.HK | INNOVENT BIO | Suzhou | China | HKD | HKG | -0.31 | -14.04 | 5568 | https://www.innoventbio.com |
300497.SZ | JIANGXI FUSHINE PH | Jingdezhen | China | CNY | SHZ | 0.14 | 35.19 | 1849 | https://www.fushine.cn |
300147.SZ | XIANGXUE PHARMACEU | Guangzhou | China | CNY | SHZ | 0.59 | 374.63 | 3378 | https://www.xphcn.com |
BLUE | bluebird bio, Inc. | Cambridge | United States | USD | NMS | 1.38 | -0.35 | 518 | https://www.bluebirdbio.com |
300204.SZ | STAIDSON (BEIJING) | Beijing | China | CNY | SHZ | 0.16 | -27.06 | 873 | https://www.staidson.com |
AKBA | Akebia Therapeutics, Inc. | Cambridge | United States | USD | NGM | 1.47 | -0.16 | 426 | https://www.akebia.com |
1873.HK | VIVA BIOTECH | Shanghai | China | HKD | HKG | 0.95 | 15.94 | 2127 | https://www.vivabiotech.com.cn |
300363.SZ | PORTON PHARMA SOLU | Chongqing | China | CNY | SHZ | -0.36 | 30.90 | 4158 | https://www.porton.cn |
VLON | Vallon Pharmaceuticals Inc. | Philadelphia | United States | USD | NCM | -1.15 | -0.24 | 2 | https://www.vallon-pharma.com |
SRNE | Sorrento Therapeutics, Inc. | San Diego | United States | USD | NCM | 2.17 | -2.59 | 799 | https://www.sorrentotherapeutics.com |
NVAX | Novavax, Inc. | Gaithersburg | United States | USD | NMS | 1.58 | -2.58 | 1541 | https://www.novavax.com |
300759.SZ | PHARMARON BEIJING | Beijing | China | CNY | SHZ | 0.28 | 49.23 | 14923 | https://www.pharmaron.com |
300404.SZ | BOJI MEDICAL & TEC | Guangzhou | China | CNY | SHZ | -0.10 | 63.41 | 989 | https://www.bojicro.com |
RIGL | Rigel Pharmaceuticals, Inc. | South San Francisco | United States | USD | NMS | 1.66 | -2.33 | 165 | https://www.rigel.com |
688180.SS | SHANGHAI JUNSHI BIOSCIENCES CO | Shanghai | China | CNY | SHH | 0.24 | -39.92 | 2805 | https://www.junshipharma.com |
600161.SS | BEIJING TIANTAN BIOLOGICAL PROD | Beijing | China | CNY | SHH | 0.02 | 23.29 | 3933 | https://www.tiantanbio.com |
9939.HK | KINTOR PHARMA-B | Suzhou | China | HKD | HKG | -0.77 | -5.99 | 316 | https://www.kintor.com.cn |
VERU | Veru Inc. | Miami | United States | USD | NCM | -0.41 | -41.18 | 252 | https://www.verupharma.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.